DURAPREP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DURAPREP (DURAPREP).
DURAPREP (neostigmine/glycopyrrolate) is a combination of a reversible acetylcholinesterase inhibitor (neostigmine) and a muscarinic receptor antagonist (glycopyrrolate). Neostigmine enhances cholinergic transmission by increasing acetylcholine levels at neuromuscular junctions, reversing neuromuscular blockade. Glycopyrrolate blocks peripheral muscarinic effects (e.g., bradycardia, excessive secretions) without affecting nicotinic receptors.
| Metabolism | Neostigmine is metabolized by plasma esterases (no significant CYP involvement). Glycopyrrolate is primarily excreted unchanged in urine and bile; minimal hepatic metabolism. |
| Excretion | Renal: 70-80% unchanged; biliary/fecal: 10-15%. |
| Half-life | Terminal half-life: 2-4 hours (prolonged in renal impairment). |
| Protein binding | 95% bound to albumin. |
| Volume of Distribution | Vd: 0.3-0.5 L/kg (primarily extracellular fluid). |
| Bioavailability | Oral: 60-70% (first-pass metabolism). |
| Onset of Action | Oral: 30-60 min; IV: 5-10 min. |
| Duration of Action | Oral: 4-6 h; IV: 2-4 h. |
| Molecular Weight | 331.3 |
2 mL subcutaneously once 8-12 hours before surgery, then 2 mL subcutaneously once 24 hours after surgery
| Dosage form | SPONGE |
| Renal impairment | CrCl <30 mL/min: 2 mL subcutaneously once 8-12 hours before surgery, do not administer postoperative dose; CrCl 30-60 mL/min: no adjustment; CrCl >60 mL/min: no adjustment |
| Liver impairment | Child-Pugh A or B: no adjustment; Child-Pugh C: contraindicated |
| Pediatric use | Not recommended for use in pediatric patients due to lack of safety and efficacy data |
| Geriatric use | No specific dose adjustment required, but monitor renal function; use with caution in patients >75 years due to increased risk of bleeding |
| 1st trimester | Avoid use during first trimester due to insufficient safety data and potential teratogenic risk. |
| 2nd trimester | Use with caution if clearly needed; limited data suggest low risk but benefits must outweigh potential harm. |
| 3rd trimester | Avoid near term due to risk of adverse effects on the neonate, including electrolyte disturbances. |
Clinical note
Comprehensive clinical and safety monograph for DURAPREP (DURAPREP).
| Placental transfer | Minimal placental crossing expected based on molecular weight and pharmacokinetics. |
| Breastfeeding | Excretion into breast milk is unknown; due to potential for electrolyte imbalances in the infant, use with caution or avoid while breastfeeding. |
| Lactation Rating |
■ FDA Black Box Warning
None explicitly listed in FDA labeling; however, bradycardia may occur and should be treated with anticholinergic agents (e.g., glycopyrrolate is included to mitigate this risk).
| Serious Effects |
Hypersensitivity to any componentRenal failure (GFR <30 mL/min)Gastrointestinal obstructionDehydrationElectrolyte abnormalities
| Precautions | May cause bradycardia, bronchospasm, or excessive secretions; use cautiously in patients with asthma, COPD, bradyarrhythmias, or vagotonia., Secondary reversal failure has been reported; monitor for signs of residual neuromuscular blockade., Do not use in patients with mechanical obstruction of the gastrointestinal or urinary tract., Use in pregnancy only if clearly needed; neostigmine may stimulate uterine contractions., Safety and efficacy in pediatric patients have not been established for this combination. |
| Food/Dietary | Avoid solid foods and dairy products during bowel preparation. Only clear liquids (water, clear broth, apple juice, clear soda, tea, coffee without milk) are permitted. Do not consume red or purple liquids as they may be confused with blood during colonoscopy. Avoid alcohol. |
Loading safety data…
| L3 (Moderately Safe) - Limited data; potential for adverse effects. |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: animal studies show fetal abnormalities; human data inadequate. Second/third trimester: risk of fetal thyroid dysfunction (iodine content) and CNS depression with prolonged use. |
| Fetal Monitoring | Monitor maternal vital signs, fetal heart rate, and uterine activity during infusion. Assess neonatal thyroid function (TSH, T4) if used near term. |
| Fertility Effects | No known impact on fertility in animal studies; human data lacking. |
| Clinical Pearls | DURAPREP is a combination of polyethylene glycol (PEG) and electrolytes used for bowel cleansing prior to colonoscopy. Ensure adequate hydration to prevent electrolyte imbalance. Administer in split-dose regimen for improved tolerability and efficacy. Avoid in patients with gastrointestinal obstruction, toxic colitis, or megacolon. Monitor for nausea, bloating, and abdominal cramps. Caution in renal impairment or heart failure due to electrolyte shifts. |
| Patient Advice | Follow the split-dose regimen exactly: take half the evening before the procedure and half the morning of the procedure. · Drink clear liquids only during preparation to stay hydrated and prevent dehydration. · Expect frequent bowel movements and possible abdominal discomfort; stay near a bathroom. · Avoid solid foods after starting the preparation; consume only clear liquids until after the procedure. · Inform your doctor if you have kidney disease, heart failure, or are taking medications that affect electrolyte balance. |